Review of Cellulitis Treatment Recommendations
Cellulitis is defined as an infection of the skin and soft tissue beneath the skin. The infection is usually due to bacteria that are commonly present on the skin or inner surface of the nose or mouth of otherwise normal and healthy people, most commonly staphylococci or streptococci. Cellulitis develops when there is a break in the skin such as a wound or injury, which may be minor or even go unnoticed. This break allows bacteria to pass through the outer layer of the skin and multiply, causing infection and swelling. Many cases of cellulitis are mild and heal completely with antibiotic treatment. However, some can be severe and lead to generalized infection. Thus, it is imperative to seek medical care promptly if the infection is associated with fever, rapid spreading and other signs of progression, or other medical conditions such as diabetes are present.1
Certain conditions increase the risk for developing cellulitis (Table 1), but it can occur in patients without known risk factors.1 The onset of cellulitis may be gradual or sudden. The most common symptom of cellulitis is pain or tenderness. Other cellulitis symptoms include swelling, warmth, redness in a distinct area of skin, and red streaking with associated lymphadenopathy along the lymphatic pathways. Symptoms commonly worsen and the redness may expand over the course of hours or days. Itching is not a typical symptom of cellulitis. The skin is usually smooth and shiny rather than raised and bumpy. Occasionally in cases of cellulitis, blisters or small pimples form on the skin. The most common areas of the body for cellulitis to develop include the legs and the arms.1
Table 1: Risk factors for developing cellulitis |
Recent injury to the skin (a wound, abrasion, cut, shaving, or injection drug use) |
The presence of a fungal or viral skin infection such as athlete’s foot or chicken pox |
Accumulation of fluid (edema) due to poor circulation, heart failure, liver disease or past surgery to remove lymph nodes |
Chronic skin conditions such as eczema |
Obesity |
Prior radiation therapy |
Weakened immune system from conditions such as diabetes, leukemia, HIV/AIDS or medications such as corticosteroids or TNF-α inhibitor |
Blood cultures and cutaneous aspirates, biopsies, or swabs are not routinely recommended except in patients with malignancy undergoing chemotherapy, neutropenia, severe immunodeficiency, immersion injuries, and animal bites.
Appropriate treatment of cellulitis involves selecting antibiotic therapy based on a patient’s symptoms and risk factors (Table 2). Patients that do not have systemic inflammatory response syndrome (SIRS), altered mental status, or hemodynamic instability can generally be treated on an outpatient basis. Poorly adherent or severely immuno-compromised patients and those that have deep or necrotizing infections should be hospitalized and treated with IV antibiotics. In conjunction with antibiotic therapy, antiinflammatory treatment with systemic corticosteroids or ibuprofen has demonstrated more rapid clinical resolution of cellulitis and may be considered in non-diabetic adults as long as deeper infections are not present (i.e., necrotizing fasciitis). The duration of antibiotic therapy for uncomplicated cellulitis is usually 5 days but may be longer if the infection is slow to resolve. It is recommended that the affected area be elevated during treatment. It is also important to treat underlying contributing conditions such as tinea pedis, venous eczema, etc.
Table 2: Selection of antibiotic therapy2 | ||
Without systemic signs of infection (typical, uncomplicated, mild non-purulent cellulitis) | Should receive an antibiotic active against streptococci | 1. monotherapy of oral beta-lactams (penicillin, amoxicillin, amoxicillin clavulanate, dicloxacillin, cephalexin)
2. oral clindamycin monotherapy |
With systemic signs of infection (moderate non-purulent) | · Intravenous antibiotics indicated
· Consider an antibiotic with methicillin-susceptible S. aureus (MSSA) coverage |
1. penicillin (no MSSA coverage)
2. nafcillin, oxacillin, dicloxacillin 3. cefazolin, cephalexin 4. clindamycin 5. doxycycline, minocycline 6. sulfamethoxazole/trimethoprim |
Cellulitis associated with:
· Penetrating trauma · Evidence of MRSA (methicillin-resistant S. aureus) including nasal colonization · Intravenous drug use · Purulent discharge · SIRS |
Antibiotic selection should provide coverage of MRSA and streptococci | Intravenous route vancomycin, daptomycin, linezolid, tedizolid or telavancinOral Route clindamycin (monotherapy)sulfamethoxazole/trimethoprim + beta-lactam doxycycline + beta lactam |
Severely immunocompromised patients | Broad-spectrum antibiotics should be considered | 1. vancomycin + piperacillin/tazobactam
2. vancomycin + imipenem or meropenem |
Recurrent cellulitis | · Identification and treatment of underlying conditions such as edema, obesity, venous insufficiency, etc.
· Antibiotic prophylaxis: consider in patients who have had 3-4 episodes of cellulitis per year despite management of predisposing factors. Long-term prophylaxis considered if underlying conditions are chronic/persistent |
Oral penicillin or erythromycin twice daily for 4-52 weeks
Intramuscular benzathine penicillin every 2-4 weeks (preferred if patient has no identifiable predisposing factors) |
- Baddour LM. Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics). In UpToDate [Internet]. Wellesley (MA): UpToDate, Inc; c2015 [updated 2014 Jun 24; cited 2015 Jan 30]. Available from: www.uptodateonline.com
- Stevens DL, Bisno AL, Chambers HF, et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 20014 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. July 15, 2014 2014:59(2):e10-e52.
Archives
- October 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- November 2018
- September 2018
- July 2018
- June 2018
- February 2018
- December 2017
- November 2017
- September 2017
- July 2017
- May 2017
- February 2017
- January 2017
- December 2016
- October 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- February 2016
- January 2016
- November 2015
- October 2015
- September 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012